EE03420B1 - Farmatseutiline kompositsioon maania ja bipolaarse häire raviks - Google Patents

Farmatseutiline kompositsioon maania ja bipolaarse häire raviks

Info

Publication number
EE03420B1
EE03420B1 EE9700302A EE9700302A EE03420B1 EE 03420 B1 EE03420 B1 EE 03420B1 EE 9700302 A EE9700302 A EE 9700302A EE 9700302 A EE9700302 A EE 9700302A EE 03420 B1 EE03420 B1 EE 03420B1
Authority
EE
Estonia
Prior art keywords
bipolar disorder
pharmaceutical composition
treating mania
mania
treatment
Prior art date
Application number
EE9700302A
Other languages
English (en)
Estonian (et)
Other versions
EE9700302A (et
Inventor
Chandra Pande Atul
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE9700302A publication Critical patent/EE9700302A/xx
Publication of EE03420B1 publication Critical patent/EE03420B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
EE9700302A 1995-05-15 1996-04-26 Farmatseutiline kompositsioon maania ja bipolaarse häire raviks EE03420B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/440,570 US5510381A (en) 1995-05-15 1995-05-15 Method of treatment of mania and bipolar disorder
PCT/US1996/005898 WO1996036328A1 (en) 1995-05-15 1996-04-26 A method of treatment of mania and bipolar disorder

Publications (2)

Publication Number Publication Date
EE9700302A EE9700302A (et) 1998-06-15
EE03420B1 true EE03420B1 (et) 2001-06-15

Family

ID=23749281

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700302A EE03420B1 (et) 1995-05-15 1996-04-26 Farmatseutiline kompositsioon maania ja bipolaarse häire raviks

Country Status (19)

Country Link
US (1) US5510381A (de)
EP (1) EP0825857B1 (de)
JP (1) JPH11505244A (de)
AT (1) ATE218857T1 (de)
AU (1) AU702435B2 (de)
CA (1) CA2215923C (de)
CZ (1) CZ288072B6 (de)
DE (1) DE69621799T2 (de)
DK (1) DK0825857T3 (de)
EE (1) EE03420B1 (de)
ES (1) ES2177783T3 (de)
GE (1) GEP20002014B (de)
HU (1) HUP9802087A3 (de)
NO (1) NO315967B1 (de)
NZ (1) NZ307366A (de)
PT (1) PT825857E (de)
SK (1) SK281982B6 (de)
WO (1) WO1996036328A1 (de)
ZA (1) ZA963826B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
HUP0004310A3 (en) * 1997-10-27 2001-11-28 Warner Lambert Co Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
ID26395A (id) * 1998-05-15 2000-12-21 Warner Lambert Comapny Turunan asam gamma-aminobutirat yang mengandung komposisi padat dan proses pembuatannya
CA2327285C (en) 1998-05-15 2005-06-14 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
EP1082306A1 (de) 1998-05-26 2001-03-14 Warner-Lambert Company Aminosäureverbindungen mit starrer konformation mit affinität für die alpha2delta untereinheit eines calciumkanals
JP2002520277A (ja) 1998-07-09 2002-07-09 ワーナー−ランバート・カンパニー 不眠症を治療する方法
EP1121114B1 (de) * 1998-10-16 2007-01-10 Warner-Lambert Company Llc Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen
BR0011236A (pt) 1999-06-02 2002-03-05 Warner Lambert Co Amino heterociclos úteis como agentes farmacêuticos
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
CN1447684A (zh) * 2000-06-16 2003-10-08 特瓦制药工业有限公司 具有在可控制范围内的pH值的稳定的加巴喷丁
PL359872A1 (en) * 2000-06-26 2004-09-06 Warner-Lambert Company Gabapentin analogues for sleep disorders
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP2575798B1 (de) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosierungszubereitung von gaba analoga
WO2015144825A1 (en) 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
US11670410B1 (en) * 2022-04-13 2023-06-06 Green Sky Creations LLC Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression

Also Published As

Publication number Publication date
MX9707269A (es) 1997-11-29
GEP20002014B (en) 2000-04-10
DK0825857T3 (da) 2002-09-30
NO315967B1 (no) 2003-11-24
WO1996036328A1 (en) 1996-11-21
ATE218857T1 (de) 2002-06-15
CZ288072B6 (cs) 2001-04-11
US5510381A (en) 1996-04-23
NO975234D0 (no) 1997-11-14
EP0825857A1 (de) 1998-03-04
EP0825857B1 (de) 2002-06-12
DE69621799D1 (de) 2002-07-18
HUP9802087A3 (en) 1999-08-30
SK281982B6 (sk) 2001-09-11
PT825857E (pt) 2002-11-29
NO975234L (no) 1997-11-14
AU5668996A (en) 1996-11-29
CZ355897A3 (cs) 1998-02-18
ES2177783T3 (es) 2002-12-16
CA2215923A1 (en) 1996-11-21
NZ307366A (en) 1999-10-28
AU702435B2 (en) 1999-02-18
DE69621799T2 (de) 2003-01-02
EE9700302A (et) 1998-06-15
SK152897A3 (en) 1999-05-07
JPH11505244A (ja) 1999-05-18
ZA963826B (en) 1996-11-21
CA2215923C (en) 2001-10-09
HUP9802087A2 (hu) 1998-12-28

Similar Documents

Publication Publication Date Title
EE03420B1 (et) Farmatseutiline kompositsioon maania ja bipolaarse häire raviks
CA2344407A1 (en) Method for the treatment of mania and bipolar disorder
BR9708632A (pt) Composto calcilìticos
DE59608698D1 (de) Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure
ATE275966T1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
ATE119770T1 (de) Verwendung von acetyl l-carnitin zur therapeutischen behandlung von coma.
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
DE69626987D1 (de) Pharmaceutische komposition
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
ES2090703T3 (es) Medicamento agudo que contiene flurbiprofeno y su empleo.
BR9811643A (pt) Suplementação quìmica de osso
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
DE69901805D1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
BR9713514A (pt) Novo uso de creatina
MX9201825A (es) Composicion farmaceutica que contiene calcitonina.
NO984197D0 (no) Fremgangsmåte for behandling av autisme
BR9701455A (pt) Uso de antagonistas de bradicinina para a preparaçao de medicamentos para o tratamento de doenças fibrogenéticas crônicas do fígado e doenças agudas do fígado
NZ328198A (en) a pharmaceutical composition containing hydroxyzine and a serotonin uptake inhibitor
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
ATE245421T1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
BR9906350A (pt) Composição contendo cetanserina e l-carnitina ou uma alcanoil l-carnitina para o tratamento de crps
YU40098A (sh) Upotreba olanzapina za dobijanje leka
ES2139382T3 (es) Sistema terapeutico percutaneo para compuestos de silatran.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

MM4A Lapsed by not paying the annual fees

Effective date: 20080426